Lee B, Kwon Y, Shin S, Kwon T, Park H, Lee H
Toxicol Res. 2024; 40(4):599-611.
PMID: 39345743
PMC: 11436705.
DOI: 10.1007/s43188-024-00251-2.
Chen W, Geng D, Chen J, Han X, Xie Q, Guo G
Cancer Cell Int. 2024; 24(1):101.
PMID: 38462618
PMC: 10926661.
DOI: 10.1186/s12935-024-03280-x.
Lu Y, Wu M, Xu Y, Yu L
Cancers (Basel). 2023; 15(14).
PMID: 37509223
PMC: 10377496.
DOI: 10.3390/cancers15143560.
Chinnam M, Xu C, Lama R, Zhang X, Cedeno C, Wang Y
PLoS Genet. 2022; 18(5):e1010171.
PMID: 35588102
PMC: 9119546.
DOI: 10.1371/journal.pgen.1010171.
Bartnykaite A, Savukaityte A, Ugenskiene R, Dauksaite M, Korobeinikova E, Gudaitiene J
J Clin Med. 2021; 10(4).
PMID: 33669778
PMC: 7922970.
DOI: 10.3390/jcm10040866.
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment.
Zhang X, Meng T, Cui S, Feng L, Liu D, Pang Q
Front Oncol. 2021; 10:621294.
PMID: 33643919
PMC: 7905169.
DOI: 10.3389/fonc.2020.621294.
Binding Ensembles of -MDM2 Peptide Inhibitors by Combining Bayesian Inference and Atomistic Simulations.
Lang L, Perez A
Molecules. 2021; 26(1).
PMID: 33401765
PMC: 7795311.
DOI: 10.3390/molecules26010198.
Inhibition of p53 inhibitors: progress, challenges and perspectives.
Sanz G, Singh M, Peuget S, Selivanova G
J Mol Cell Biol. 2019; 11(7):586-599.
PMID: 31310659
PMC: 6735775.
DOI: 10.1093/jmcb/mjz075.
Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated and MDM2 up-regulation.
Tracz-Gaszewska Z, Klimczak M, Biecek P, Herok M, Kosinski M, Olszewski M
Oncotarget. 2017; 8(47):82123-82143.
PMID: 29137250
PMC: 5669876.
DOI: 10.18632/oncotarget.18899.
Bioinformatics analysis of the prognostic value of Tripartite Motif 28 in breast cancer.
Hao L, Leng J, Xiao R, Kingsley T, Li X, Tu Z
Oncol Lett. 2017; 13(4):2670-2678.
PMID: 28454449
PMC: 5403292.
DOI: 10.3892/ol.2017.5764.
Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice.
Leroy B, Ballinger M, Baran-Marszak F, Bond G, Braithwaite A, Concin N
Cancer Res. 2017; 77(6):1250-1260.
PMID: 28254861
PMC: 7457206.
DOI: 10.1158/0008-5472.CAN-16-2179.
Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.
Hernandez-Monge J, Rousset-Roman A, Medina-Medina I, Olivares-Illana V
Genes Cancer. 2017; 7(9-10):278-287.
PMID: 28050229
PMC: 5115168.
DOI: 10.18632/genesandcancer.120.
Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.
Micewicz E, Sharma S, Waring A, Luong H, McBride W, Ruchala P
Int J Pept Res Ther. 2016; 22(1):67-81.
PMID: 26957954
PMC: 4779441.
DOI: 10.1007/s10989-015-9487-3.
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo S, Low D
J Clin Invest. 2015; 126(1):68-84.
PMID: 26595814
PMC: 4701541.
DOI: 10.1172/JCI82534.
Targeting Mdmx to treat breast cancers with wild-type p53.
Haupt S, Buckley D, Pang J, Panimaya J, Paul P, Gamell C
Cell Death Dis. 2015; 6:e1821.
PMID: 26181202
PMC: 4650725.
DOI: 10.1038/cddis.2015.173.
Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B, Bouarich-Bourimi R, Leemput J, Lejour V, Hamon A, Plancke L
Oncogene. 2014; 34(22):2943-8.
PMID: 25088193
DOI: 10.1038/onc.2014.230.
The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
Lu M, Xia L, Li Y, Wang X, Hoffman R
Blood. 2014; 124(5):771-9.
PMID: 24869939
PMC: 4467881.
DOI: 10.1182/blood-2013-11-536854.
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang Y, Graves B, Guerlavais V, Tovar C, Packman K, To K
Proc Natl Acad Sci U S A. 2013; 110(36):E3445-54.
PMID: 23946421
PMC: 3767549.
DOI: 10.1073/pnas.1303002110.
Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.
Jin L, Sturgis E, Zhang Y, Huang Z, Wei P, Guo W
Carcinogenesis. 2013; 34(7):1551-7.
PMID: 23508638
PMC: 3697893.
DOI: 10.1093/carcin/bgt096.
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q, Lozano G
Clin Cancer Res. 2012; 19(1):34-41.
PMID: 23262034
PMC: 3537867.
DOI: 10.1158/1078-0432.CCR-12-0053.